-
Peripheral T-cell lymphoma (PTCL)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsMellalta’s analysts estimate that the United States market is expected to show rapid growth, mainly attributed to, the launch of Adcetris in the front-line setting and expected approval of the potential therapies in the pipeline during the forecast period (2021-2030). Through this, the market size is set to show an extensive jump and grow at a CAGR of 15.3%
-
Metastatic Renal cell carcinoma (mRCC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCurrently, tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies are widely used in first- and second-line treatments for mRCC. Despite the current treatments, there remains the unmet need for early diagnosis and treatment options. Emerging drugs in development like Dovitinib (Allarity Therapeutics) and Savolitinib/ AZD6094 (Astrazeneca), and others will expand the first-line and second-line settings for patients with mRCC and likely to address the current unmet needs for the treatment of mRCC. The upcoming treatment options for mRCC can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.
-
Metastatic Ovarian Cancer (mOC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Metastatic Ovarian Cancer (mOC) market is relatively large with highest market share holding drugs in 2022 i.e., Olaparib and Niraparib. By 2032, the market is expected to change due to the loss of patents of the current therapies and the uptake and launch of new therapies. In a mOC treatment setting, the Olaparib will consistently perform and will grasp the highest market share followed by other emerging drugs. The sales of the emerging therapies for the treatment of mOC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 5.3 billion by 2032.
-
Chronic Kidney Disease (CKD) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the Prevalence CKD population will contribute to increasing sales in the CKD therapy market over our forecast period. An estimated annual growth rate of 0.4% in the Prevalent CKD population across the major pharmaceutical markets will contribute to increasing CKD therapy sales. In 2019, there were approximately 94 million prevalent cases of CKD in the major markets; we expect the number of cases will exceed 2.08 million in 2032 owing to changes in population demographics and increasing cases of CKD associated conditions such as anemia, hyperphosphatemia, secondary hyperthyroidism, diabetes kidney disease and cardiovascular patients group.
The continuous involvement of supportive treatments including renal replacement therapies for the management of dialysis dependent CKD patients will contribute to the the overall growth of the CKD therapy market. We forecast that total sales of the total current RRTs market will reach more than $13 billion by 2032.
-
Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsAbout 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist. CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2022-2032 study period, adding an estimated value to a total more than $1 billion market by 2032
-
Acute Kidney Injury (AKI) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2 million in 2032 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.
The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $XX billion by 2032.
Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.
Renal Diseases / Nephrology
Home » Therapeutic Area » Renal Diseases / Nephrology
